1. Home
  2. ECL vs ALNY Comparison

ECL vs ALNY Comparison

Compare ECL & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ecolab Inc.

ECL

Ecolab Inc.

HOLD

Current Price

$257.43

Market Cap

73.6B

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$404.43

Market Cap

60.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECL
ALNY
Founded
1923
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.6B
60.1B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
ECL
ALNY
Price
$257.43
$404.43
Analyst Decision
Buy
Strong Buy
Analyst Count
16
27
Target Price
$294.27
$483.89
AVG Volume (30 Days)
1.5M
1.1M
Earning Date
10-28-2025
10-30-2025
Dividend Yield
1.13%
N/A
EPS Growth
N/A
N/A
EPS
6.95
0.33
Revenue
$15,890,400,000.00
$3,210,070,000.00
Revenue This Year
$3.03
$69.60
Revenue Next Year
$5.35
$42.67
P/E Ratio
$37.05
$1,226.18
Revenue Growth
1.38
53.24
52 Week Low
$221.62
$205.87
52 Week High
$286.04
$495.55

Technical Indicators

Market Signals
Indicator
ECL
ALNY
Relative Strength Index (RSI) 41.44 32.73
Support Level $251.75 $420.30
Resistance Level $276.62 $479.79
Average True Range (ATR) 4.78 17.95
MACD -1.24 -4.21
Stochastic Oscillator 22.78 0.83

Price Performance

Historical Comparison
ECL
ALNY

About ECL Ecolab Inc.

Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the US market and is growing its presence abroad.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: